ArticleChemistry & biodiversity2026
Isoquercitrin Alleviates 5-Fluorouracil-Induced Intestinal Mucositis in Mice by Modulating Inflammation and Oxidative Stress.
Article in Chemistry & biodiversity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
This study aimed to evaluate the role of isoquercitrin (ISO) in 5-fluorouracil-induced intestinal mucositis. The animals (6 animals/group) were divided into: vehicle (2% DMSO), 5-fluorouracil (5-FU) and groups receiving ISO (10, 50, or 100 mg/kg). ISO at 100 mg/kg (ISO-100) (232.5 ± 3.8 µm) attenuated the reduction in villus height induced by 5-FU (125.3 ± 1.5 µm) and the reduction in crypt depth in the intestine (ISO-100: 101.7 ± 3.5 µm vs 5-FU: 70.8 ± 1.6 µm; p < 0.05). The jejunum was chosen for assays involving oxidative stress and inflammation. ISO-100 attenuated the mastocytosis (ISO-100: 7.6 ± 0.1 mast cells/field vs 5-FU: 12.5 ± 0.2 mast cells/field; p < 0.05) and goblet cell depletion (ISO-100: 11.0 ± 0.5 cells/field vs 5-FU: 8.0 ± 0.6 cells/field; p < 0.05). The treatment with ISO-100 showed lower levels of MDA and MPO, and increased GSH levels. Administration of celecoxib (selective COX-2 inhibitor) + ISO-100 increased the villus height and the immunohistochemistry showed that ISO-100 + CLX (7.4% ± 0.1%) attenuates the expression of COX-2 in jejunum induced by 5-FU (22.5% ± 0.1%). These results show that ISO-100 attenuates 5-FU-induced intestinal mucositis by modulating the inflammatory process and reducing oxidative stress.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.